We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App





Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology

By LabMedica International staff writers
Posted on 15 Nov 2023
Print article
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)
Image: Magnetic 3D bioprinting offers new possibilities in high-throughput screening (Photo courtesy of Greiner Bio-One)

Greiner Bio-One (Monroe, NC, USA) is highlighting its magnetic 3D (M3D) cell culture technology which opens up new possibilities in high-throughput screening at MEDICA 2023.

M3D bioprinting combined with cell-repellent surfaces is a superior technology for enabling the miniaturization and speed needed for high-throughput screening. M3D bioprinting enables the uniform generation and ease of manipulation of spheroids/organoids for high-throughput screening by directing magnetized cells to assemble in a controllable size within a shorter culture time. Thus, this technology surpasses the limitations of other high-throughput screening platforms. For improving predictiveness and reducing false positives of high-throughput screening, M3D has shown to be an effective and superior tool to power faster, cheaper, and better results. Moreover, 3D cell culture methodologies are often not easily scalable, meaning that the assumption that one technique used on primary screening is translatable into secondary ones is often inaccurate. A clear benefit for M3D has been its scalability, using the same workflow for high and low throughputs and delivering consistent.

At MEDICA 2023, Greiner Bio-One is also showcasing its safe, effective, and reliable blood collection products for hospitals and clinics. The company’s VACUETTE Safety Products ensure safety and comfort during blood sampling while protecting healthcare staff from blood-borne infections. By using safety products, staff protection is maximized and there is no risk of infection. For the safe transport of samples to the laboratory, Greiner Bio-One offers the VACUETTE – Transport Line range of transport containers of different dimensions in which the Vacuette is transported in an upright position. The transport bags are made of a special isothermal material that maintains a constant temperature of the samples. The transport system protects the samples from heat and mechanical influences. The transport bags also provide storage space for the accompanying medical documentation.

Related Links:
Greiner Bio-One

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.